Business
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
ZUG, Switzerland, March 03, 2026 (GLOBE NEWSWIRE) -- Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market o
About this update from Oculis Holding Ag
[{"type":"image","alt":"Oculis Holding AG","displaySize":"","headline":null,"caption":"Oculis Holding AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/8ad7f9a35e702253b405c1e1f0eb1cf9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9Tx1uuuzsErM0lxb4iyrCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8ad7f9a35e702253b405c1e1f0eb1cf9","width":300,"height":75}},"lazy":false},{"type":"text","content":"ZUG, Switzerland, March 03, 2026 (GLOBE NEWSWIRE) --","length":52,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) in Q2 2026 ","length":249,"tagName":"p"}]},{"val":[{"type":"text","content":"Key expansion in neuro-ophthalmology with Breakthrough Therapy designation granted to Privosegtor, propelling the PIONEER registrational program in optic neuropathies with a potential U.S. market opportunity of over $7 billion ","length":226,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents, and short-term investments of $268.7 million as of December 31, 2025, providing cash runway into 2029","length":130,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":605,"olType":false},{"type":"text","content":"Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the fourth quarter and full year ended December 31, 2025, and provided an overview of the Company’s progress.","length":347,"tagName":"p"},{"type":"text","content":"Riad Sherif, M.D., Chief Executive Officer of Oculis, stated “Oculis has delivered a transformative 2025, marked by significant clinical progress across our late-stage portfolio and a strategic expansion into neuro-ophthalmology. The compelling Phase 2 ACUITY results for Privosegtor in optic neuritis led to a pivotal FDA Breakthrough Therapy designation and anchored the launch of our global PIONEER registrational program. We believe ...